bioMérieux Pandemic Preparedness 

bioMérieux is contributing its expertise in infectious disease diagnostics to the global effort to address the Influenza A/H1N1 pandemic.  

New product development

bioMérieux is adapting its NucliSENS EasyQ® Influenza A/B test to include this new H1N1 strain. 

Support through our current product offering

bioMérieux’s NucliSENS® easyMAG® instrument is already being used for extraction of Influenza viral nucleic acids at several public health laboratories in the world. bioMérieux is currently building stock of specific reagents to face the global demand. Extraction of nucleic acids is an initial step in diagnostic or confirmatory testing on molecular diagnostic platforms.

bioMérieux is also ramping up its production and supply capacity to support customers in the vaccine industry who use the company’s culture media range for the control and release of vaccines.

bioMérieux distributes Quidel’s QuickVue® Influenza A+B and QuickVue Influenza A/B rapid tests, which provide results in under 10 minutes. The effectiveness of these tests to detect the H1N1 strain is currently being evaluated and has not been demonstrated.